GoKawiilAlex Zhavoronkov, founder and co-chief executive of techbio company Insilico, is among the scientists who have devoted countless hours to studying aging.
Insilico’s Co-CEO Has Big Hopes That Fibrosis Drug Can Reverse Aging Too
Why This Matters
Insilico Medicine, an AI-driven drug discovery company, is positioning its lead fibrosis candidate as a potential anti-aging therapy, reflecting a growing willingness to test longevity claims through conventional clinical pipelines. If a drug developed largely with AI shows benefits beyond its original indication, it would be a notable validation of both techbio methods and aging-focused biology.
Key Takeaways
- Insilico co-CEO Alex Zhavoronkov, a longtime aging researcher, hopes the company's fibrosis drug can also reverse aspects of aging.
- The bet ties AI-based drug discovery to the still-unproven longevity field, where regulatory paths remain unclear.
- Pursuing a recognized disease indication first is a pragmatic way for longevity companies to reach the clinic.
Get alerts for these topics